
1-29 fragment of endogenous GHRH — the most clinically studied secretagogue, with decades of use in pediatric GH deficiency.
Not in stock yet. Message us on WhatsApp and we'll let you know as soon as it arrives.
Ranges cited in research literature. Not a usage recommendation. For research use only.
Sermorelin is fragment 1-29 of human growth-hormone-releasing hormone (GHRH), with the native sequence and an amidated C-terminus. Those 29 amino acids are the minimal portion of GHRH's 44 with full biological activity, and it was the first molecule of the class to reach the clinic: Serono marketed it as Geref, approved by the FDA in the 1990s as a diagnostic test of pituitary reserve and for pediatric GH deficiency.
It acts on the GHRH receptor in somatotroph cells of the anterior pituitary and triggers a GH release that respects physiological regulation: the response still depends on somatostatin and on IGF-1 feedback, so secretion stays pulsatile and self-limiting. Its half-life is 10 to 20 minutes, the shortest of the GHRH analogs in the catalog, because DPP-4 rapidly cleaves the first two amino acids.
Geref was withdrawn from the market in 2008 for commercial, not safety, reasons, and since then sermorelin has existed mostly as a research compound. Together with tesamorelin it is the GHRH analog with the most human data: decades of clinical use, trials in children and adults and a well-characterized tolerability profile (local reactions, facial flushing). It shares the class considerations on GH and IGF-1 and is on the World Anti-Doping Agency list. Renova distributes it as the acetate, for research only.
| Class | GHRH analog, native amidated 1-29 fragment |
| Sequence | Human GHRH(1-29)-NH2 (29 aa), acetate salt |
| CAS | 86168-78-7 (sermorelin) · 114466-38-5 (acetate) |
| Receptor | GHRH receptor (anterior pituitary) |
| Half-life | 10–20 minutes (DPP-4 degradation) |
| Regulatory history | FDA-approved as Geref (diagnostic and pediatric GH deficiency); withdrawn 2008 for commercial reasons |
| Difference from Mod GRF 1-29 | Native sequence, without the 4 stabilizing substitutions |
| Current status | Research compound; WADA list (S2) |
Yes. Under the name Geref (Serono) it held FDA approval as a diagnostic test of pituitary function and for GH deficiency in children. It was withdrawn from the market in 2008 by Serono's commercial decision, not over safety problems. Renova's product is research material, not that medicine.
Because it keeps GHRH's natural sequence and the DPP-4 enzyme clips its first two amino acids within minutes, inactivating it. Mod GRF 1-29 (CJC-1295 without DAC) and tesamorelin carry modifications that block that cut; sermorelin does not.
Sermorelin is the native 1-29 fragment with a 10–20 minute half-life; tesamorelin is full-length GHRH (1-44) with a hexenoyl group at the N-terminus that protects it from DPP-4 and makes it last longer. Tesamorelin holds current approval as a medicine (Egrifta); sermorelin had it and lost it for commercial reasons.
In research it is common to pair GHRH analogs with ghrelin-receptor agonists (ipamorelin, GHRP-6) because the two classes potentiate each other. Sermorelin, with its short half-life, generates brief pulses; our CJC-1295 + Ipamorelin stack guide explains the principle, applicable to any GHRH analog.
Related reading: CJC-1295 + Ipamorelin: The Most-Studied GH Stack · Tesamorelin: GHRH Analog and Visceral Fat
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty